Bayer, Dr. Reddy’s Ink Distribution Deal for Vericiguat™ in India

Hyderabad India; April 6, 2024 – Dr. Reddy’s Laboratories Ltd. and Bayer introduced that each corporations have entered right into a partnership to market and distribute a second model of Vericiguat in India. Under the phrases of this settlement, Bayer has granted non-exclusive rights to Dr. Reddy’s beneath the model identify Gantra®. Vericiguat, a soluble guanylate cyclase (sGC) stimulator, in India, is indicated, together with guideline-based medical remedy, in adults with symptomatic persistent coronary heart failure with lowered ejection fraction (lower than 45%), following a latest occasion of worsening coronary heart failure which required hospitalization or outpatient intravenous (IV) diuretics 6 . Vericiguat works on a pathway not at present focused by current coronary heart failure remedies and might scale back the mixed threat of
cardiovascular loss of life and coronary heart failure hospitalization in such affected person 7 , 8 . India has between 8-10 million individuals with coronary heart failure, making it one of many largest populations with this situation 9 .

Shweta Rai, Managing Director, Bayer Zydus Pharma and Country Division Head (CDH) for Bayer’s Pharmaceuticals Business in South Asia stated, “Despite remedy, persistent coronary heart failure sufferers can expertise illness development that disrupts their lives and results in worsening coronary heart failure occasions. Vericiguat will help decelerate illness development, scale back hospital admissions and enhance their probabilities of survival 10 , 11 . The introduction of a second model of vericiguat in India, by